Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy
In the investigated cohort, a second course of adjuvant melanoma treatment is feasible and provides similar RFS compared to an initial course of adjuvant therapy using BRAF + MEK inhibitors; however, RFS2 is reduced for PD-1 antibodies. In addition, both treatments were convincing with a 24-month OS of almost 100%. Switching from adjuvant PD-1 to BRAF + MEK treatment provided better overall RFS compared to switching from adjuvant BRAF + MEK to PD-1 treatment.
Authors
- Ulrike Schultheis
- Kai Christian Klespe
- Lara Valeska Maul (ORCID: https://orcid.org/0000-0001-9202-0073)
- Erika Richtig (ORCID: https://orcid.org/0000-0002-5505-6103)
- Magdalena Hoellwerth (ORCID: https://orcid.org/0000-0002-2771-4041)
- Marina Wanner
- Miriam Mengoni (ORCID: https://orcid.org/0000-0002-1651-7114)
- Andreas Braun (ORCID: https://orcid.org/0000-0002-6954-0633)
- Cornelia Mauch (ORCID: https://orcid.org/0000-0002-3989-0536)
- Christian Posch (ORCID: https://orcid.org/0000-0003-0296-3567)
- Klemens Rappersberger (ORCID: https://orcid.org/0009-0004-7420-7132)
- Alexander Thiem (ORCID: https://orcid.org/0000-0001-9504-4281)
- Tilo Biedermann (ORCID: https://orcid.org/0000-0002-5352-5105)
- Carmen Loquai
- Steffen Emmert (ORCID: https://orcid.org/0000-0001-5630-4204)
- Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
- Veronika Zenderowski
- Sevil Börger
- Van Anh Nguyen (ORCID: https://orcid.org/0000-0003-2087-447X)
- Wiebke K. Peitsch (ORCID: https://orcid.org/0000-0003-2478-2951)
- Katharina Schumann
- Johanna Mangana
- W. Harth
- O.D. Persa
- Peter Koelbinger
- Frank Meis
Institutions
- Sigmund Freud Privatuniversität Wien (AT)
- Innsbruck Medical University (AT)
- University of Freiburg (DE)
- Johannes Gutenberg University Mainz (DE)
- Medical University of Graz (AT)
- University of Zurich (CH)
- Paracelsus Medical University (AT)
- University Medical Center Freiburg (DE)
- University Hospital Regensburg (DE)
- Klinik Hietzing (AT)
- University Hospital of Zurich (CH)
- Vivantes Klinikum (DE)
- München Klinik (DE)
- University Hospital Magdeburg (DE)
- Austrian Competence Centre of Food Safety (AT)
- Klinikum Bremen-Mitte (DE)
- University Hospital Cologne (DE)
- University of Rostock (DE)
- Technical University of Munich (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1111/jdv.20708
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Celgene
- Therakos
- Freiwillige Akademische Gesellschaft
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Recordati Rare Diseases
- Incyte
- Galderma
- Sun Pharma
- LEO Pharma